Home Alzheimer’s Disease AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19

AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19

AstraZeneca plans to conduct a global clinical trial to assess the effect of acalabrutinib (Calquence) on the exaggerated immune response of patients who are severely ill with the coronavirus disease 2019 (COVID-19) infection, according to a press release.

The trial design was based on strong scientific and early clinical data on the Bruton’s tyrosine kinase (BTK) pathway and its role in the production of inflammatory cytokines. The trial hopes to evaluate safety and efficacy of adding acalabrutinib to best supportive care in an attempt to reduce mortality and assisted ventilation requirements for patients with strong COVID-19 symptoms.

“With this trial we are responding to the novel insights of the scientific community and hope to demonstrate that adding Calquence to best supportive care reduces the need to place patients on ventilators and improves their chances of survival,”…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Recent Comments